Medical regulators: look beyond animal tests

Comment

Merel Ritskes-Hoitinga. Nature. 2022 Apr.

. 2022 Apr;604(7907):599.

doi: 10.1038/d41586-022-01110-6.

No abstract available

Keywords: Medical research; Policy.

Comment on

Utility of In Vitro Bioactivity as a Lower Bound Estimate of In Vivo Adverse Effect Levels and in Risk-Based Prioritization.
Paul Friedman K, Gagne M, Loo LH, Karamertzanis P, Netzeva T, Sobanski T, Franzosa JA, Richard AM, Lougee RR, Gissi A, Lee JJ, Angrish M, Dorne JL, Foster S, Raffaele K, Bahadori T, Gwinn MR, Lambert J, Whelan M, Rasenberg M, Barton-Maclaren T, Thomas RS. Paul Friedman K, et al. Toxicol Sci. 2020 Jan 1;173(1):202-225. doi: 10.1093/toxsci/kfz201. Toxicol Sci. 2020. PMID: 31532525 Free PMC article.